Article in Life science alliance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Eleanor HargreavesInstitute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, UK.ORCID 0000-0002-9287-8480
Rebecca CollinsonCentre for Genome Engineering and Maintenance, Department of Biosciences, College of Health, Medicine and Life Sciences, Brunel University London, London, UK.ORCID 0009-0005-9760-9393
Andrew D JenksDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.ORCID 0009-0005-1724-5412
Adina StaszewskiCentre for Genome Engineering and Maintenance, Department of Biosciences, College of Health, Medicine and Life Sciences, Brunel University London, London, UK.
Athanasios TsalikisDepartment of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.ORCID 0000-0003-4994-4312
Raquel BodoqueChester Beatty Laboratories, Institute of Cancer Research, London, UK.
Mar Arias-GarciaChester Beatty Laboratories, Institute of Cancer Research, London, UK.ORCID 0000-0003-0130-1107
Yasmin AbdiCentre for Genome Engineering and Maintenance, Department of Biosciences, College of Health, Medicine and Life Sciences, Brunel University London, London, UK.
Abdulaziz Al-MalkiChester Beatty Laboratories, Institute of Cancer Research, London, UK.
Yinyin YuanChester Beatty Laboratories, Institute of Cancer Research, London, UK.ORCID 0000-0002-8556-4707
Rachael NatrajanThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID 0000-0002-9987-2946
Syed HaiderThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID 0000-0001-6685-5480
Thomas IskratschSchool of Engineering and Materials Science, Faculty of Science and Engineering, Queen Mary University of London, Engineering Building, London, UK.ORCID 0000-0002-3738-7830
Won-Jing WangInstitute of Biochemistry and Molecular Biology, College of Life Science, National Yang-Ming University, Taipei, Taiwan.ORCID 0000-0001-9733-0839
Susana GodinhoCentre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0003-0638-065X
Nicolaos J PalaskasDavid Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID 0000-0003-0783-0683
Fernando CalvoInstituto de Biomedicina y Biotecnología de Cantabria (Consejo Superior de Investigaciones Científicas, Universidad de Cantabria), Santander, Spain.ORCID 0000-0001-8858-1185
Igor VivancoInstitute of Pharmaceutical Science, King's College London, London, UK.ORCID 0000-0001-6347-9416
Tobias ZechInstitute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, UK.ORCID 0000-0001-8394-088X
Barbara E TanosCentre for Genome Engineering and Maintenance, Department of Biosciences, College of Health, Medicine and Life Sciences, Brunel University London, London, UK.ORCID 0000-0002-7045-9496
Funding
The Cancer Genome Atlas Pilot Project / NCI and NHGRIUniversity of Liverpool MR/X013502/1
6 · The paper itself
Abstract
Centriole and/or cilium defects are characteristic of cancer cells and have been linked to cancer cell invasion. However, the mechanistic bases of this regulation remain incompletely understood. Spindle assembly abnormal protein 6 homolog (SAS-6) is essential for centriole biogenesis and cilium formation. SAS-6 levels decrease at the end of mitosis and G1, resulting from APC
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.